Bone drugs' safety doubted

Share this article:
A new U.S. Food and Drug Administration analysis raises questions about long-term effectiveness among women of the widely prescribed osteoporosis drugs known as bisphosphonates.

The safety of the bone-building drugs, which include brands such as Boniva and Reclast, has been a topic of debate. The FDA's analysis found that after three to five years of use, bisphosphonates offer little to no benefit.

FDA reviewers said it's possible long-term use of the drugs could actually weaken bones, leading to adverse events such as femur fractures and esophageal cancer.
Share this article:
close

Next Article in News

More in News

Double homicide at Houston nursing home; victims' roommate arrested

Double homicide at Houston nursing home; victims' roommate ...

A double murder occurred late Tuesday night in a Houston nursing home room shared by four men, according to local authorities. Police arrested Guillermo Correa on suspicion of beating two ...

$2 million HIPAA settlement highlights mobile device risks facing healthcare providers

Laptops and other mobile devices containing personal health information have been stolen from long-term care ombudsman programs and other healthcare organizations, including from Concentra Health Services and QCA Health Plan Inc. Now, Concentra and QCA have agreed to legal settlements totaling nearly $2 million, federal ...

Long-term care nurses often 'scramble' to get family members' blessing for palliative ...

Nursing home residents might not transition to full palliative care until they are very near death, at which point nurses and family members act in a state of crisis, suggests recently published research out of Canada.